Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases
2017/08/19 by Susanna Nikolaus, Berenice Schulte, Natalie Al-Massad +16 · 597 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Amino acid #Biochemistry #Bioinformatics #Biology #Colitis #Disease #Feces #Gastroenterology #Gut microbiota and health #Immunology #Inflammatory Bowel Disease #Inflammatory bowel disease #Internal medicine #Medicine #Microbiology #Microbiome #Tryptophan #Tryptophan and brain disorders #Ulcerative colitis
paper · doi:10.1053/j.gastro.2017.08.028
published in Gastroenterology 153(6), 1504-1516.e2 (Elsevier BV)
openalex publication_date 2017/08/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
BACKGROUND & AIMS: Administration of tryptophan and some of its metabolites reduces the severity of colitis in mice, whereas removing tryptophan from the diet increases susceptibility to colitis. Transfer of the intestinal microbiome transfers the colitogenic phenotype from tryptophan starved animals to normally nourished mice. We aimed to systematically evaluate serum levels of tryptophan and its metabolites in patients with inflammatory bowel diseases (IBD), and study their association with clinical and serologic features. METHODS: We studied 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled in Germany from August 2013 through April 2014 and followed until July 2016. Serum samples were collected from patients and 291 matched individuals without IBD (controls); levels of tryptophan were measured using high-performance liquid chromatography. Metabolites of tryptophan were measured in serum from 148 patients and 100 controls by mass spectrometry. We measured levels of interleukin 22 in serum from 28 patients by enzyme-linked immunosorbent assay. Paired stool and serum samples were collected from a subset of patients with active UC (n = 10) or CD (n = 8) to investigate associations between serum levels of tryptophan and composition of the fecal microbiota, analyzed by 16S ribosomal DNA amplicon sequencing. We used real-time polymerase chain reaction to measure levels of messenger RNAs in colonic biopsies from 60 patients with UC, 50 with CD, and 30 controls. We collected information on patients' disease activity scores, medications, laboratory assessments, and clinical examinations during recruitment and follow-up visits. RESULTS: ). We found a negative correlation between serum levels of tryptophan and disease activity or levels of C-reactive protein. Levels of messenger RNAs encoding tryptophan 2,3-dioxygenase-2 and solute carrier family 6 member 19 (also called B0AT1) were significantly decreased in colonic biopsies from patients with IBD compared with controls, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increased. The composition of the fecal microbiota associated with serum levels of tryptophan. Analysis of tryptophan metabolites revealed activation of the kynurenine pathway, based on high levels of quinolinic acid, in patients with IBD compared with controls. Serum concentration of interleukin 22 associated with disease activity in patients with IBD; there was an inverse association between levels of interleukin 22 and serum levels of tryptophan. CONCLUSIONS: In an analysis of serum samples from more than 500 patients with IBD, we observed a negative correlation between serum levels of tryptophan and disease activity. Increased levels of tryptophan metabolites-especially of quinolinic acid-indicated a high activity of tryptophan degradation in patients with active IBD. Tryptophan deficiency could contribute to development of IBD or aggravate disease activity. Interventional clinical studies are needed to determine whether modification of intestinal tryptophan pathways affects the severity of IBD.
Cited by
- Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine
- Essential Amino Acid Metabolites as Chemical Mediators of Host-Microbe Interaction in the Gut
- The Gut Microbiome and Inflammatory Bowel Diseases
- Novel cross-feeding human gut microbes metabolizing tryptophan to indole-3-propionate
- Gut Microbial Metabolites of Aromatic Amino Acids as Signals in Host–Microbe Interplay
- Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the gut
- Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort
- Cytochrome P450 Cyp2s1 regulation of the intestinal metabolome and microbiome
- Life-long microbiome rejuvenation improves intestinal barrier function and inflammaging in mice
- β-ionone prevents dextran sulfate sodium-induced ulcerative colitis and modulates gut microbiota in mice
- Tryptophan metabolism in health and disease
- Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development
- Gut microbiota-derived metabolites as key actors in inflammatory bowel disease
- Tryptophan‐derived serotonin‐kynurenine balance in immune activation and intestinal inflammation
- Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. [europepmc]
- Microbial tryptophan catabolites in health and disease. [europepmc]
- ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS-STING. [europepmc]
- The Role of Dietary Nutrients in Inflammatory Bowel Disease. [europepmc]
- Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota. [europepmc]
- Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. [europepmc]
- Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine. [europepmc]
- Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. [europepmc]
- Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease. [europepmc]
- The Effects of Nutrition on the Gastrointestinal Microbiome of Cats and Dogs: Impact on Health and Disease. [europepmc]
- Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. [europepmc]
- The aryl hydrocarbon receptor as a mediator of host-microbiota interplay. [europepmc]
- Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases. [europepmc]
- Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation. [europepmc]
- Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease. [europepmc]
- The Gut Microbiome and Inflammatory Bowel Diseases. [europepmc]
- Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. [europepmc]
- New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases. [europepmc]
- The Gut Microbiota in Inflammatory Bowel Disease. [europepmc]
- Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. [europepmc]
- Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease. [europepmc]
- Repression of the aryl-hydrocarbon receptor prevents oxidative stress and ferroptosis of intestinal intraepithelial lymphocytes. [europepmc]
- Inflammatory Bowel Diseases and Gut Microbiota. [europepmc]
- The Tryptophan and Kynurenine Pathway Involved in the Development of Immune-Related Diseases. [europepmc]
- Microbiota-derived indoles alleviate intestinal inflammation and modulate microbiome by microbial cross-feeding. [europepmc]
Related